相关实验视频
Updated: Jun 26, 2025

CD Spectroscopy to Study DNA-Protein Interactions
Published on: February 10, 2022
在缺乏SMARCB1的肉瘤中对PGBD5依赖的DNA损伤的表观遗传向
Yaniv Kazansky1,2, Helen S Mueller1,2, Daniel Cameron1,2
1Molecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
将EZH2表观遗传疗法与ATR抑制相结合,在治疗SMARCB1缺乏的癌症方面表现有前途. 这种方法针对DNA损伤途径,改善了表皮状和状瘤的治疗反应.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症生物学 癌症生物学
背景情况:
- 大多数癌症对当前的表观遗传药物没有反应,限制了它们的治疗潜力.
- 作为一种EZH2抑制剂的塔泽美托斯被批准用于SMARCB1缺陷的上皮类瘤,原因是PRC2和SMARCB1损失之间的功能对抗性.
- 之前的研究确定了患者瘤对EZH2表观遗传疗法的反应和耐药性原则.
结论:
- EZH2和ATR抑制的组合为治疗特定癌症类型提供了合理的方法.
- 这一策略适合用于针对相关瘤类型的患者的临床试验.
- 推进一种基于合成致命依赖的新型组合表观遗传疗法.
更多相关视频
09:14Examination of Proteins Bound to Nascent DNA in Mammalian Cells Using BrdU-ChIP-Slot-Western Technique
Published on: January 14, 2016
06:44Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
Published on: April 28, 2021
相关概念视频
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against...
Epigenetic Regulation
X-chromosome...
Negative Regulator Molecules
Base Excision Repair
The first step of...
DNA Damage can Stall the Cell Cycle